Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Pb Multiple | 3.9x - 4.4x | 4.1x |
| Historical Pb Multiple | 2.8x - 6.2x | 3.9x |
| Fair Value | $634.38 - $701.15 | $667.76 |
| Upside | -1.1% - 9.3% | 4.1% |
| Benchmarks | - | Full Ticker |
| Revvity, Inc. | - | DB:PKN |
| Pharmaron Beijing Co., Ltd. | - | DB:17Q1 |
| Eurofins Scientific SE | - | ENXTPA:ERF |
| Agilent Technologies, Inc. | - | DB:AG8 |
| Sartorius Aktiengesellschaft | - | DB:SRT |
| Lonza Group AG | - | OTCPK:LZAG.F |
| Select Price / Book Ratio | ||||||||
| Benchmark Companies | ||||||||
| PKN | 17Q1 | ERF | AG8 | SRT | LZAG.F | |||
| DB:PKN | DB:17Q1 | ENXTPA:ERF | DB:AG8 | DB:SRT | OTCPK:LZAG.F | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | 4.4% | 26.8% | 19.6% | 3.8% | -11.7% | -0.3% | ||
| 3Y CAGR | -31.7% | 2.6% | -21.9% | 2.1% | -35.9% | -1.9% | ||
| Latest Twelve Months | 57.7% | 12.0% | 38.9% | 1.9% | -59.1% | -2.8% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | 18.9% | 17.1% | NA | 17.6% | 12.7% | 23.5% | ||
| Prior Fiscal Year | 6.5% | 13.9% | 3.9% | 18.1% | 6.1% | 9.7% | ||
| Latest Fiscal Year | 10.3% | 14.6% | 5.1% | 19.8% | 2.5% | 9.7% | ||
| Latest Twelve Months | 10.3% | 14.6% | 5.1% | 19.3% | 2.5% | 9.7% | ||
| Return on Equity | ||||||||
| 5 Year Average Margin | 10.9% | 14.9% | NA | 21.2% | 22.8% | 9.0% | ||
| Prior Fiscal Year | 2.4% | 13.9% | NA | 22.2% | 10.1% | 6.5% | ||
| Latest Twelve Months | 3.6% | 13.7% | NA | 20.6% | 3.5% | 6.8% | ||
| Next Fiscal Year | 7.6% | 12.8% | 13.0% | 26.9% | 11.6% | 12.5% | ||
| Two Fiscal Years Forward | 8.2% | 14.2% | 13.6% | 28.6% | 13.6% | 14.4% | ||
| Current Trading Multiples | ||||||||
| Price / LTM Sales | 4.1x | 3.0x | NA | 4.4x | 3.3x | 5.6x | ||
| Price / LTM EPS | 39.5x | 20.5x | NA | 22.6x | 134.8x | 57.9x | ||
| Price / Book | 1.5x | 2.7x | NA | 4.7x | 4.1x | 3.9x | ||
| Price / Fwd Book | 1.4x | 3.0x | 0.0x | 5.3x | 4.0x | 3.9x | ||
| Low | Mid | High | ||||||
| Benchmark P/B Ratio | 1.5x | 3.4x | 4.7x | |||||
| Historical P/B Ratio | 2.8x | 3.9x | 6.2x | |||||
| Selected P/B Multiple | 3.9x | 4.1x | 4.4x | |||||
| (x) Book Value | 9,328 | 9,328 | 9,328 | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | PKN | 17Q1 | ERF | AG8 | SRT | LZAG.F | |
| Value of Common Equity | 11,344 | 44,036 | 0 | 31,424 | 12,215 | 37,152 | |
| (/) Shares Outstanding | 120.1 | 3,776.4 | 0.0 | 285.1 | 77.9 | 70.6 | |
| Implied Stock Price | 94.41 | 11.66 | 46.83 | 110.22 | 156.80 | 525.97 | |
| FX Conversion Rate to Trading Currency | 1.13 | 8.27 | 1.00 | 1.13 | 1.00 | 0.82 | |
| Implied Stock Price (Trading Cur) | 83.32 | 1.41 | 46.83 | 97.27 | 156.80 | 641.29 | |
| Trading Currency | EUR | EUR | EUR | EUR | EUR | USD | |
| FX Rate to Reporting Currency | 1.13 | 8.27 | 1.00 | 1.13 | 1.00 | 0.82 | |